Medeva Changes Tack
Executive Summary
Criticized for not properly managing growth, Medeva's managers contend they're building a sustainable business. They used profits from methylphenidate, an off-patent treatment for attention deficit disorder, to finance a long list of acquisitions, many of which didn't work out. When methylphenidate sales crashed with the entrance of generic competition, so did Medeva's credibility with investors. They're hoping their self-sustaining European and American infrastructure will help them attract the higher-risk, higher profit products they shunned in their original strategy but now need in order to dig themselves out of their profit hole.You may also be interested in...
Impella Safety Update: Data Supports Pump For Qualified Patients
Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.
Quality, Safety, MDSAP A Focus For Medtech In New USMCA Trade Agreement
The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.
Novo Nordisk Targets Smart Insulin, Stem Cell-Therapies
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.
Need a specific report? 1000+ reports available
Buy Reports